Diasorin affonda in Borsa: la guidance 2026 non convince e il mercato rivede le stime

DiaSorin's guidance miss for 2026 combined with a breach of decade-long support levels represents a structurally bearish technical and fundamental setup. The diagnostics sector continues to face post-COVID revenue normalization headwinds, and a guidance disappointment at multi-year lows signals that management itself lacks visibility on a recovery trajectory convincing enough for markets. The market's re-rating of 2026 estimates implies consensus EV/EBITDA and P/E multiples may need further compression before new buyers emerge. Sentiment of -75 with 85% confidence from independent analysis reinforces conviction that institutional selling pressure is not exhausted, particularly if analyst downgrades cascade in the coming days. ⚡ DEEP SONNET: Short entry on any intraday technical relief bounce toward the broken support level (now resistance), ideally within 2-4% of current price. Avoid chasing the gap down at open; wait for intraday stabilization then fade the bounce. Key level to watch: prior multi-year support converted to resistance. | TP:10% SL:5% | 2–4 weeks | Risk:HIGH — The primary risk on a short position is a V-shaped capitulation reversal or unexpected M&A approach at distressed valuations. Additional risks include ECB rate cycle pivot boosting Italian equities broadly, short-squeeze if positioning becomes crowded, and any positive mid-cycle update or FDA/CE approval news that could short-circuit the bearish thesis. On the long side, fundamental risk remains elevated given unclear 2026 earnings visibility. | Sizing:CONSERVATIVE